



**11:00 –12:50**

**GSK's vaccine, cervical cancer protection designed to last**

**Salle des Princes auditorium**

---

Chair: T. Wright

Co-chair: H. Bogaerts

---

11:00-11:20 Evolving understanding of endpoints for HPV vaccination trials

X. Bosch

---

11:20-11:40 The need for a strong and sustained immune response  
to prevent cervical cancer:

The value of the AS04 adjuvant system

---

M. Stanley

---

11:40-12:10 Clinical overview of GSK's AS04-adjuvanted cervical cancer vaccine:  
Safety, efficacy, and immunogenicity in women 15-25 years of age

D. Harper

---

Safety and immunogenicity data in girls & women 10 to 55 yrs of age

---

T. Schwarz

---

12:10-12:30 Vaccination to prevent cervical cancer:  
Public and individual health perspective

T. Wright

---

Practical considerations for Europe

---

P. Van Damme

---

12:30-12:50 Q&A

---



**16:30 –18:00**

## Protecting Women's Health Together: Our Mission – Their Reality

Salle des Princes auditorium

---

Chairperson: Dr L. Villa

---

Wider impact on Women's Health: Beyond the Uterine Cervix

Dr M. Hampl (Germany)

---

Understanding the Science: Dispelling the Myths

Pr M. Stanley (UK)

---

GARDASIL®: Setting the standards for HPV vaccines

Dr A. Guiliano (US)

---

Protecting women's health together:

The role of HPV vaccination and Cervical cancer screening

Pr C. Clavel (France)

---

Delivering the benefit: Making the choice

Dr L. Villa (Brasil)

---

Closing remarks

Q & A

Dr L. Villa (Brasil)



**17:00 –18:30**

**The Clinical Utility of p16 as a Biomarker  
in Cervical Cancer Screening**

**Prince Pierre Auditorium**

---

Introduction : The clinical needs for biomarkers in cervical cancer screening

Professor Tom Wright

---

Improving diagnostic accuracy and inter-observer agreement with p16  
in cervical histology

Dr. Ordi

---

Clinical role of the p16 biomarker in improving the effectiveness of  
cytology interpretations

Dr. Bergeron

---

Use of the cervatec p16 Elisa together with PAP cytology substantially increases the  
detection rate for CIN2+

Prof. Petry



**7:00 – 8:00**

**Direct Detection of Oncogene Expression.  
New Strategies in Cervical Cancer Prevention.**

**Van Dongen Room**

---

**Chairmen**

FRANK KARLSEN (NORCHIP), MARCEL JACOBS (BIOMÉRIEUX)

---

**Perspectives on HPV testing by mRNA**

DR. IVAN SILVA - Norway  
Senior Scientist, NorChip AS

---

**HPV DNA and mRNA testing in the Irish Cervical Screening Population**

DR. CARA M. MARTIN - Ireland  
Department of Histopathology, University of Dublin, Trinity College, Dublin 2

---

**Experience with HPV-proofer testing in ASCUS - an interim presentation**

DR. BRITT M. WIEBE - Denmark  
Department of Pathology, Herlev Hospital, University of Copenhagen,

---

**Development of a NucliSENS EasyQ E6/E7 mRNA assay for the detection of  
5 oncogenic HPV types in cervical smears**

MARCEL JACOBS - Netherlands  
Senior Manager - Assay Development Molecular Diagnostics Boxtel - bioMérieux



## Diagnostics

18:00 –19:30

Salle des Princes auditorium

---

**Improved genotype-specific concordance with use of standardized PCR-based assays**

Patti Gravitt, MS, PhD

*Assistant Professor of Epidemiology*

Johns Hopkins Bloomberg School of Public Health

Baltimore, MD USA

---

**Human papillomavirus genotype prevalence in women diagnosed with cervical intraepithelial neoplasia**

Sepehr Tabrizi, MS, PhD

*Associate Professor*

Faculty of Medicine, Dentistry and Health

Department of Obstetrics and Gynaecology

University of Melbourne

*Senior Research Scientist*

Division of Laboratory Services

Department of Microbiology

The Royal Women's Hospital - Carlton, Australia



a QIAGEN company

**11:00 –12:30**

**Adapted Screening Strategies with HPV Testing  
– Practical Experiences and Future Directions**

Prince Pierre auditorium

---

**Chair**

Professor Tom Wright

---

**11:00-11:20 Routine Screening Program using HPV Testing plus Pap  
– 18 months Experience in Wolfsburg**

Professor Dr. Karl Ulrich Petry

- Klinikum der Stadt Wolfsburg, Wolfsburg, Germany

---

**11:20-11:40 Practical Experiences with HPV Primary Screening**

Dr. Walter Kinney

- Kaiser Permanente Medical Group Inc., Sacramento, USA

---

**11:40-12:00 New Model for Cervical Cancer Prevention  
– Vaccination and Adapted Screening**

Professor Chris Meijer

- Vrije Universiteit Medical Center (VUMC), Amsterdam, The Netherlands

---

**12:00-12:20 Questions and Answers**

---



**18:00 –19:00**

**Incontinence urinaire : avancées en 2007**

**Bosio Room**

**PRÉSIDENT**

---

Professeur Alain Pigné (Paris)

**ORATEURS**

---

Docteur Calin Ciufu (hôpital Tenon Paris)

Madame Joëlle Souffir (Paris)